Hologic Reports Gains in Non-COVID Diagnostics, Surgical Products
Company beats its Q3 earnings guidance on strength of women's health diagnostics income, and CEO Steve MacMillan predicted relief from chip supply problems
Hologic Preliminary Fiscal Q1 Revenues Drop 9 Percent
The firm expects fiscal Q1 Diagnostics revenues of $950.4 million, down 16 percent compared to the prior-year quarter when its COVID-19 revenues surged.
The company has invested revenues from its pandemic testing business to buy assets that are growing faster than its base business.
Hologic to Acquire Finnish MDx Firm Mobidiag for Approximately $795M
Hologic intends to invest in assay development for Mobidiag's Novodiag PCR platform, which provides high-level multiplexing to detect infectious disease organisms.
Mobidiag SARS-CoV-2, Influenza A/B, RSV Test Receives CE Mark
The firm said it is currently also developing Novodiag Resp-4, a molecular test for the rapid, on-demand detection of the viruses.